Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Looks For New Chair To Lead It Through New Strategic Direction

Executive Summary

GSK’s non-exec chairman steps down from the UK firm, just a month after announcing a split that will reshape the company.

You may also be interested in...



Pfizer Consumer Combo Deal Frees Capital For GSK Pharma Investment

Separating out its consumer business in a joint venture with Pfizer will open up investment possibilities for GlaxoSmithKline's pharma and vaccine businesses.

New CFO Mackay Completes Top Table At GSK

CEO Emma Walmsley’s plans to transform the leadership at GSK have advanced again with the appointment of HSBC's Iain Mackay as the firm's new chief financial officer.

US FDA May Play Central Role In Assuring Access To Mifepristone Post Roe v. Wade

HHS will take steps to increase access to abortion medication and prevent states from banning it, Secretary Becerra says, but also is questioned about whether the FDA can speed up certification of pharmacies and if the Justice Department would sue states banning access.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC124518

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel